Choose a Drug ! Aciphex Acomplia Actos Acyclovir Allegra Alli Diet Drug Altace Ambien Amoxicillin Atenolol Ativan Augmentin Avandia Avapro Baclofen Bactrim Biaxin Celebrex Celexa Cephalexin Champix Cialis Cipro Claritin D Clomid Coreg Depakote Diflucan Dilantin Diovan Doxycycline Effexor XR Elavil Estradiol Flomax Flonase Fluoxetine Folic Acid Fosamax Glucophage Hydroxyzine Ibuprofen Imitrex Keflex Lamisil Lasix Levaquin Levitra Lexapro Lipitor Mobic Naproxen Neurontin Nexium Norvasc Omeprazole Paxil Plavix Premarin Prevacid Promethazine Propecia Proscar Protonix Reductil Reglan Remeron Risperdal Singulair Sonata Synthroid Tamiflu Topamax Trazodone Ultra "C" tabs Ultra "L" tabs Ultra "V" tabs Ultram Viagra Wellbutrin Xenical Zithromax Zocor Zoloft Zyban Zyprexa Zyrtec

September 2007 August 2007 July 2007 June 2007 May 2007 April 2007 March 2007 February 2007 January 2007 December 2006 November 2006 October 2006 September 2006 August 2006 July 2006 June 2006 May 2006 April 2006 March 2006 February 2006

Opt-in for Free Newsletter, special discount offers, drugs information & latest pharmacy news.

Sanofi's Acomplia Gets Limited French Reimbursement

Sanofi-Aventis said on Thursday its anti-obesity drug Acomplia would be reimbursed by French social security when prescribed to certain obese diabetics, but only after other treatment proved insufficient.

The French health authority's Transparency Committee agreed last month to recommend that Acomplia be reimbursed only when it is prescribed to obese patients with type 2 diabetes and with certain blood sugar levels.

Under conditions published on Thursday, doctors must first try out other targeted therapies and must place the patient on a special diet and physical exercise, Sanofi said.

In France, patients generally pay for their medication and are reimbursed in part by the social security service, and get all or most of the rest back through employer mutual schemes.

Sanofi had originally applied for wider permission for Acomplia to be reimbursed for obesity with associated risks.

Source:http://www.reuters.com/